"A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) AS MONOTHERAPY FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)-(KEYNOTE-086),"
- Registry ID
- 086
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MERCK CANADA INC
- Start date
- 2016-09-28
- Completion date
- 2019-11-15
- Last update
- 2015-06-11
Conditions
- BREAST CANCER METASTATIC TRIPLE NEGATIVE
Related clinical trials
- A PHASE III, MULTISITE, RANDOMIZED, DOUBLE-BLIND TRIAL OF BNT327 IN COMBINATION WITH CHEMOTHERAPY VERSUS PLACEBO WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY RECURRENT INOPERABLE OR METASTATIC TNBC DETERMINED INELIGIBLE FOR PD(L)1 THERAPY BASED ON PD-L1 NEGATIVE DISEASE
- A RANDOMIZED, OPEN-LABEL, PHASE 2/3 STUDY OF IZALONTAMAB BRENGITECAN (BMS-986507) VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, RECURRENT INOPERABLE, OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) OR ER-LOW, HER2-NEGATIVE BC WHO ARE INELIGIBLE FOR ANTI-PD1/PD-L1 TREATMENT
- A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATODXD) IN COMBINATION WITH DURVALUMAB COMPARED WITH INVESTIGATOR'S CHOICE OF CHEMOTHERAPY (PACLITAXEL, NAB-PACLITAXEL OR GEMCITABINE + CARBOPLATIN) IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-L1 POSITIVE LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TROPIONBREAST05).
- A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN AND PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN¿S CHOICE AND PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE, OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, WHOSE TUMORS EXPRESS PD-L1
- A PHASE 3, OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATODXD) VERSUS INVESTIGATOR¿S CHOICE OF CHEMOTHERAPY IN PATIENTS WHO ARE NOT CANDIDATES FOR PD 1/PD L1 INHIBITOR THERAPY IN FIRST-LINE LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TROPION BREAST02)
- AN OPEN-LABEL, RANDOMIZED, PHASE 2/3 STUDY OF OLAPARIB PLUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY PLUS PEMBROLIZUMAB AFTER INDUCTION OF CLINICAL BENEFIT WITH FIRST-LINE CHEMOTHERAPY PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) (KEYLYNK-009)
View on source registry